RxDoctor Payments Data

Kristina Hair, DO

Family Medicine · Lakeland, FLNPI 1700268703

Payments from drug & device makers

$2,151in general payments, 2019–2025

Across 109 payments — averaging $19.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$482
  • Novo Nordisk$284
  • AbbVie$230
  • Pfizer$192
  • Biohaven Pharmaceutical Holding Company Ltd.$128
  • GSK$128
  • plus $707 from 15 others

What the payments were for

  • Food & beverage$2,151100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,151 in reported general payments places this provider in the 75th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$45,192
Medicare patients
194
Services billed
533

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide22$24,793
EliquisApixaban23$23,859
JardianceEmpagliflozin14$16,895
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$10,309
SomaCarisoprodol12$10,026
Humalog Kwikpen U-100Insulin Lispro14$2,389
SynthroidLevothyroxine Sodium26$1,801
Atorvastatin Calcium134$1,357
Levalbuterol Tartrate HfaLevalbuterol Tartrate12$1,296
Omeprazole63$1,123
Levothyroxine Sodium84$1,080
Ventolin HfaAlbuterol Sulfate18$971
Amlodipine Besylate126$758
Celecoxib11$702
Rosuvastatin Calcium41$637

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$284$24,79322 claims
PfizerEliquis$192$23,85923 claims
Boehringer IngelheimJardiance$35$16,89514 claims
GSKTrelegy Ellipta$128$10,30916 claims
AbbVieSynthroid$230$1,80126 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Lakeland

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →